Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors.
"We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable as we continue to advance our proprietary gene editing technologies into the clinic and deliver on our vision to harness the power of metagenomics to create curative genetic medicines for patients."
"I'm honored to join Metagenomi's Board of Directors at such a pivotal time in the Company's evolution. Metagenomi's powerful gene editing platform is rooted in scientific rigor and has the potential to redefine the treatment landscape for patients suffering from serious genetic diseases," said Dr. Reid. "I'm thrilled to support the team in advancing its innovative pipeline and building a world-class, science-driven company."
Dr. Reid is an entrepreneur, company builder, and biotech executive, leveraging his experience as an advisor to growing biotech companies. He currently serves as chairperson of the board of directors of Broken String Biosciences Ltd. and on the boards of directors of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) and several other private biotechnology companies. Previously, Dr. Reid was president and CEO of Decibel Therapeutics, Inc., until its acquisition by Regeneron Pharmaceuticals, Inc. in 2023 and CEO of Warp Drive Bio, LLC until its merger with Revolution Medicines, Inc. in 2018. Dr. Reid has also served as an entrepreneur in residence at Third Rock Ventures LLC. Prior to that, he served as Chief Business Officer of Alnylam Pharmaceuticals, Inc., and as General Manager of Millennium Europe at Millenium Pharmaceuticals, Inc., which is now part of Takeda Pharmaceutical Company Limited. Dr. Reid received a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King's College, London University.
About Metagenomi
Metagenomi is a precision gene editing company leveraging the power of artificial intelligence and machine learning to develop the next generation of potentially curative genome editing therapeutics. Its metagenomics-derived gene editing toolbox has analyzed over 7.4 billion proteins and has the potential to target any type of genetic mutation across the entire human genome. The Company's innovative and comprehensive platform has full spectrum gene editing, with technologies ranging from ultra-small nucleases and base editors to large gene integrations using CRISPR-associated transposase (CAST) and RNA-Mediated Integration Systems (RIGS). The Company's lead, wholly-owned development program in Hemophilia A is a potentially curative therapy designed to provide life-long protection from bleeding events and joint damage in adults and children. The Company has additional wholly-owned assets in its pipeline for secreted protein deficiencies and partnered assets for cardiometabolic diseases. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as "anticipate," "believe," "could, ""estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in "Risk Factors," in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contacts:
Stephen Jasper
Gilmartin Group
[email protected]
or
Kiki Patel, PharmD
Gilmartin Group
[email protected]
